00:00
Okay.
00:01
So let's look at this cycle.
00:03
First of all, if you like
to have room ahead we've got
four cycles or stages
that we're going to talk
about in this life cycle.
00:10
The first one is
binding infusion.
00:12
The next one is conversion
and integration,
third is replication
and forth is assembly
budding and maturation.
00:20
So what you're looking at here
are the stages, the four stages
of the HIV life cycle.
00:28
Okay, cool.
00:29
We've got some
graphics for you there.
00:30
But I'm going to help you
recognize what the most
important parts are.
00:34
We're going to start
with the first stage.
00:36
I know clever,
but that's where we're going to start.
00:39
So binding and fusion.
00:41
That's the first stage
the virus attaches itself
to the T helper cell and
releases HIV into the cell.
00:49
That's the binding and fusion.
00:51
So drugs that work,
they are called
HIV Fusion Inhibitors.
00:57
So make sure you write that
down go back up to your slide
with the four
stages and write in
HIV Fusion inhibitor.
01:05
Now give you an example of
that drug in just a minute,
but I want you to
have the concept
if we can stop that Fusion.
01:11
Ah, then you can see why
we have less viral right?
Because if I stop
the fusion I'm not going
to have steps 2, 3 and 4,
so I'm not going to have extra copies
being released into the system.
01:23
Cool!
So fusion or entry
inhibitor drugs
stop this from happening.
01:29
So that's stopping it
very early in the process
before we've gone
through the other phases.
01:35
So here's an example of
one of the medications.
01:38
Make sure you circle
that drug name up there
because that's one,
I think it's really important
that you recognized
as an example
of this type of medication.
01:46
So it's an HIV Fusion inhibitor.
01:49
It's widely known as T20.
01:52
So right that back in up
at the top by the name
just to remind you
that this one is
often called T20.
01:59
It's the first and only
only HIV fusion inhibitor
and it blocks HIV from
getting into the CD4 T-cells
and it's twice daily.
02:09
Oh oh! SubQ dosing.
02:12
Okay as a health care provider,
you know what that means
right as I'm part of the team.
02:17
I have to think
about twice a day.
02:19
This patient has to have the
medication accessible to them
and they have to be comfortable
with giving themselves
a SubQ injection.
02:27
Well think back to first
day of clinical lab
when you to do
this on a partner.
02:32
It was nerve-racking right
in want to hurt them.
02:35
Well, some people can stick
other people all day long,
but when it comes to
sticking themselves,
that's another issue.
02:43
So this will involve you being
very patient with the patient
assessing how comfortable
they feel with the process
of sticking themselves
with a SubQ needle
how comfortable are
they had drawing up
medication Etc and Etc.
02:56
Can they see the syringe?
Do they have the hand
dexterity to do that?
Do they have any
issues with arthritis
and I have a difficult
time with the syringe
on and on
so it's not just enough
to tell a patient,
Yeah, this is what you do.
03:11
As a nurse I'm always thinking,
are they capable of doing this?
Do they have the
resources to do this?
Are they ready to do this
emotionally physically mentally.
03:20
Now usually this is a
pretty small adjustment
but it's still an adjustment
don't overlook that
with your patients.
03:28
So you've got these stages.
03:29
We just talked about this
drug, T20.
03:31
It's in the binding and
the fusion stage, right?
So the adverse effects can be
injection site reactions,
you know again teach the
patient how to rotate the site's
what sites are going to be most
easily accessible for the patient,
but help them to know
that injection site
reactions sometimes happen.
03:48
If they experience that
just let us know and we'll work
with them and problem-solve.
03:54
Now there's also an
increased risk for pneumonia
and it's a hypersensitivity
reactions inhibitor.
04:00
I know those are kind of weird
but those are the
three major ones
we'd be looking for with T20.